ClinicalTrials.gg
Not yet recruitingNCT07938411PINNACLE-MIUpdated Nov 16, 2026

A Study to Assess the Effect of Pacibekitug on Major Cardiovascular Events in Patients After a Myocardial Infarction

A Phase 3 interventional study of Pacibekitug and Placebo in Myocardial Infarction, sponsored by Novartis Pharmaceuticals. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
10,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Myocardial Infarction by Novartis — 2 open to participants now, 4 under way, 3 of them phase 3. Myocardial Infarction · Novartis.

Planned enrollment
4th of 13
10,000 · median 5,700
Started
2026
with 1 other
Phase 3
11 of 17
1 open now
Registered
17th of 17
by date

Among the 17 studies in Myocardial Infarction by Novartis, this one is the 4th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2026, is one of 11 in phase 3, and was the 17th registered.

Myocardial Infarction

2,272 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

2 of the 17 studies in Myocardial Infarction by Novartis are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 257 Myocardial Infarction studies recruiting now, 173 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Myocardial Infarction by Novartis, or all of them as a file.
02

Study summary

The main purpose of this study is to demonstrate the superiority of pacibekitug compared to placebo in reducing the risk of 3-point coronary major adverse cardiovascular events (3P-Coronary- MACE), defined as a composite of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), and urgent coronary revascularization, in participants after an MI, at high cardiovascular (CV) risk and receiving standard of care (SoC) secondary CV prevention therapies.

Read the detailed description

Randomized, double-blind, parallel group, placebo-controlled, multi-center, global, event-driven study evaluating pacibekitug compared to placebo.

The study will consist of an optional pre-screening period of up to \~ 15 days, a screening period of up to \~ 30 days, a double-blind treatment period and a safety follow-up call.

The study is event-driven and designed to complete when both criteria are met: (a) at least 860 participants have experienced a CEC-confirmed primary 3P-Coronary-MACE across both treatment arms, (b) at least 85% of participants have been followed for at least 1 year during the double-blind treatment period.

03

Conditions studied

  • Myocardial Infarction

Keywords

  • Pacibekitug
  • myocardial infarction (MI)
  • cardiovascular (CV)
  • major adverse cardiovascular events (MACE)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The key inclusion criteria are as follows:

  • Adults aged ≥ 18 years at the time of form (ICF) signature.
  • Diagnosis of spontaneous (type 1) MI based on medical records and the Investigator's judgment. Patients must be either:

    1. ≤ 30 days from the index MI presentation at Randomization, OR
    2. > 30 days to ≤ 12 months from the index MI presentation at Randomization AND have an elevated hsCRP ≥ 2 mg/L at Screening or optional Pre-screening
  • At high CV risk, defined as the presence of at least two of the following criteria documented in the medical records :

    1. Age ≥ 65 years.
    2. Diabetes mellitus (DM) requiring pharmacotherapy.
    3. History of a MI or coronary revascularization prior to the index MI.
    4. Multivessel coronary artery disease (CAD).
    5. Cerebrovascular disease (CeVD) comprised of either carotid artery disease or a prior ischemic stroke.
    6. Peripheral artery disease (PAD).
    7. Current active smoking (defined according to smoking status at Screening).

Exclusion criteria

Exclusion Criteria:

The key exclusion criteria are as follows:

  • Patients with the following laboratory abnormalities at Screening:

    1. (ANC) \< 1,500/μL
    2. count \< 100,000/μL
    3. (ALT) or aspartate aminotransferase (AST) > 3.0 × (ULN) or total (TBL) > 3.0 x ULN (exception: if the elevation is assessed by the Investigator as related to the acute MI, the exclusion threshold is ALT or AST > 8.0 × ULN)
    4. Estimated (eGFR) \< 60 mL/min/1.73 m2 using the CKD Epidemiology Collaboration (CKD-EPI) formula
  • Planned coronary, carotid or peripheral artery revascularizations known at Randomization. Randomization can occur after completion of all planned index MI-related single or staged percutaneous coronary interventions (PCI).
  • Coronary artery bypass graft (CABG) surgery within 6 months prior to Screening, CABG surgery after the index MI, or planned CABG surgery for the index MI.
  • Severe heart failure (known prior chronic diagnosis, or post-MI cardiac dysfunction) defined as (NYHA) class IV, pulmonary edema (Killip class III) or cardiogenic shock (Killip class IV), present at Screening or Randomization. Note: Prior clinically resolved episodes do not meet this exclusion criterion.
  • Active infection (unless minor and expected to be self-limited and non-progressive, e.g. uncomplicated upper respiratory infection), at the discretion of the Investigator.
  • Any life-threatening condition with \< 4 years from the Screening visit, other than vascular disease, that might prevent the patient from completing the study.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
10,000 participants (estimated)

Study arms

  • Experimental
    Pacibekitug

    pacibekitug s.c.

    Drug: Pacibekitug

  • Placebo comparator
    Placebo

    Placebo s.c.

    Drug: Placebo

Interventions

  • DrugPacibekitug

    pacibekitug s.c.

    Also known as: PAC001, TOUR006

  • DrugPlacebo

    Placebo s.c.

06

What researchers measure

Primary outcomes

  1. Time to the first occurrence of 3P-Coronary-MACE

    3-point Coronary major adverse cardiovascular events (3P-Coronary-MACE), defined as a composite of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), and urgent coronary revascularization

    Time frame: Up tp 1398 days

Secondary outcomes

  1. Time to the first occurrence of 4P-MACE

    4P-MACE (composite of CV death, non-fatal MI, non-fatal ischemic stroke, and urgent coronary revascularization)

    Time frame: Up tp 1398 days

  2. Time to the first occurrence of 3P-MACE

    3-point MACE (3P-MACE) defined as a composite of CV death, non-fatal MI, and non-fatal ischemic stroke

    Time frame: Up tp 1398 days

  3. Time to the first occurrence of 4P-MACE or MALE

    4P-MACE or Major Adverse Limb Events (MALE) defined as a composite of CV death, non-fatal MI, non-fatal ischemic stroke, urgent coronary revascularization, acute limb ischemia, major amputation of vascular cause, and limb revascularization

    Time frame: Up tp 1398 days

  4. Time to the first occurrence of 5P-MACE

    5P-MACE defined as a composite of CV death, non-fatal MI, non-fatal ischemic stroke, urgent coronary revascularization, and heart failure \[HF\] hospitalization or urgent visit

    Time frame: Up tp 1398 days

  5. Total number of 3P-Coronary-MACE

    Times to the occurrences of all 3P-Coronary-MACE (first and recurrent non-fatal MI and urgent coronary revascularization, and occurrence of CHD death).

    Time frame: Up tp 1398 days

  6. Total number of 4P-MACE

    Times to the occurrences of all 4P-MACE (first and recurrent non-fatal MI, non-fatal ischemic stroke, and urgent coronary revascularization, and occurrence of CV death)

    Time frame: Up tp 1398 days

  7. Time to CV death

    Time to cardiovascular (CV) death

    Time frame: Up tp 1398 days

  8. Time to all-cause mortality

    Time frame: Up tp 1398 days

  9. Number of participants with adverse events

    Number of participants with AEs, SAEs, AEs leading to discontinuation of study treatment, including abnormal safety laboratory parameters

    Time frame: Up tp 1398 days

  10. Percent change from baseline in hsCRP

    Percent change from baseline in High-sensitivity C-Reactive Protein (hsCRP)

    Time frame: Baseline, month 6

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Oct 2030, 46 months later.

Of 57 phase 3 interventional studies under Myocardial Infarction, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 77. This study's planned 46 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartEst.
Nov 30, 2026
Primary completionEst.
Oct 22, 2030
CompletionEst.
Oct 22, 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938411
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Oct 22, 2030 (estimated)
Completion
Oct 22, 2030 (estimated)
Last update
Nov 16, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
+41613241111
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion